Clinical Efficacy Analysis of Alprostadil Combined with Metformin in the Treatment of Diabetes Nephropathy
Objective To compare and analyze the clinical effect of alprostadil combined with metformin in the treat-ment of diabetes nephropathy.Methods The clinical data of 250 patients with diabetic nephropathy admitted to Nan'an Hospital from January 2022 to September 2023 were retrospectively selected.According to the drug treatment method,they were divided into control group and study group,125 cases in each group,Both groups were given basic treatment such as hypoglycemic,lipid-lowering and blood pressure lowering,the control group was given metformin treatment,and the study group was given alprostadil treatment on the basis of the comparison group,and the therapeutic effect of the two groups was compared.Results After treatment,the improvement in blood glucose levels(fasting plasma glu-cose,2-hour postprandial plasma glucose,glycated hemoglobin),renal function(blood urea nitrogen,blood creatinine,urinary albumin excretion rate),and serum levels(anticardiolipin antibodies,interleukin-6,neutrophil gelatinase re-lated lipid transport protein)in the study group were better than those in the control group,the differences were statis-tically significant(all P<0.05);the clinical treatment effective rate of the study group was 95.20％,which was higher than that of the control group(87.20％),the difference was statistically significant(x2=4.984,P<0.05).Conclusion During diabetes nephropathy,alprostadil combined with metformin can enhance clinical efficacy and improve blood glucose,renal function and serum levels.
Diabetes nephropathyAlprostadilMetforminRenal function levelBlood glucose levelsSerum level
NETL
NSTL
万方数据
